Company Logo
They are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Their lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. They have observed positive topline results in a Phase 1 clinical trial of KER-050, and they plan to initiate two Phase 2 clinical trials, one in patients with MDS and one in patients with myelofibrosis. Their lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, a rare musculoskeletal disorder, and is currently in a Phase 1 clinical trial. Their third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. They plan to progress KER-012 into a Phase 1 clinical trial in the second half of 2021. They believe these product candidates offer substantial opportunities for them to expand their development programs into related hematological and musculoskeletal disorders with high unmet medical need.